Novartis AG
Octreotide Depot Formulation with Constantly High Exposure Levels
Last updated:
Abstract:
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
Status:
Application
Type:
Utility
Filling date:
9 Feb 2021
Issue date:
3 Jun 2021